Literature DB >> 1560521

Molecular attenuation of vaccinia virus: mutant generation and animal characterization.

M S Lee1, J M Roos, L C McGuigan, K A Smith, N Cormier, L K Cohen, B E Roberts, L G Payne.   

Abstract

These studies demonstrated that the inbred BALB/c mouse strain can be optimized for the assessment of vaccinia virus virulence, growth, and spread from the site of inoculation and immune protection from a lethal vaccinia virus challenge. The studies established that manipulation of the vaccinia virus genome generated mutants exhibiting a wide range of attenuated phenotypes. The nine NYCBH vaccinia virus mutants had intracranial 50% lethal doses that ranged from 2 to greater than 7 log10 units. The decreased neurovirulence was due to decreased replication in brain tissue. Three mutants had a decreased ability to disseminate to the lungs, brains, livers, and spleens of mice after intranasal infection. One mutant had a decreased transmission from mice infected by tail scarification to naive cage mates. Although the mutants, with one exception, grew to wild-type titers in cell culture, they showed a growth potential on the scarified skin of mice that was dramatically different from that of the wild-type virus. Consequently, all of the mutants had significantly compromised immunogenicities at low virus immunization doses compared with that of the wild-type virus. Conversely, at high immunization doses most mutants could induce an immune response similar to that of the wild-type virus. Three Wyeth vaccine strain mutants were also studied. Whereas the thymidine kinase, ribonucleotide reductase, and hemagglutinin mutants had a reduced virulence (50% lethal dose), only the thymidine kinase mutant retained its immunogenicity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1560521      PMCID: PMC241015     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  22 in total

1.  The complete DNA sequence of vaccinia virus.

Authors:  S J Goebel; G P Johnson; M E Perkus; S W Davis; J P Winslow; E Paoletti
Journal:  Virology       Date:  1990-11       Impact factor: 3.616

2.  Deletion of the vaccinia virus growth factor gene reduces virus virulence.

Authors:  R M Buller; S Chakrabarti; J A Cooper; D R Twardzik; B Moss
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

3.  Delineation of the viral products of recombination in vaccinia virus-infected cells.

Authors:  D D Spyropoulos; B E Roberts; D L Panicali; L K Cohen
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

4.  Recombinant vaccinia virus LC16m0 or LC16m8 that expresses hepatitis B surface antigen while preserving the attenuation of the parental virus strain.

Authors:  M Morita; K Suzuki; A Yasuda; A Kojima; M Sugimoto; K Watanabe; H Kobayashi; K Kajima; S Hashizume
Journal:  Vaccine       Date:  1987-03       Impact factor: 3.641

5.  Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype.

Authors:  R M Buller; G L Smith; K Cremer; A L Notkins; B Moss
Journal:  Nature       Date:  1985 Oct 31-Nov 6       Impact factor: 49.962

6.  Vaccinia virus vectors utilizing the beta-galactosidase assay for rapid selection of recombinant viruses and measurement of gene expression.

Authors:  D Panicali; A Grzelecki; C Huang
Journal:  Gene       Date:  1986       Impact factor: 3.688

7.  Vaccinia virus: a selectable eukaryotic cloning and expression vector.

Authors:  M Mackett; G L Smith; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

8.  Mapping and insertional mutagenesis of a vaccinia virus gene encoding a 13,800-Da secreted protein.

Authors:  G J Kotwal; A W Hügin; B Moss
Journal:  Virology       Date:  1989-08       Impact factor: 3.616

9.  Recombinant vaccinia virus expressing Epstein-Barr virus glycoprotein gp340 protects cottontop tamarins against EB virus-induced malignant lymphomas.

Authors:  A J Morgan; M Mackett; S Finerty; J R Arrand; F T Scullion; M A Epstein
Journal:  J Med Virol       Date:  1988-06       Impact factor: 2.327

10.  Localization of a herpes simplex virus neurovirulence gene dissociated from high-titer virus replication in the brain.

Authors:  R T Javier; K M Izumi; J G Stevens
Journal:  J Virol       Date:  1988-04       Impact factor: 5.103

View more
  37 in total

1.  Skin mast cells protect mice against vaccinia virus by triggering mast cell receptor S1PR2 and releasing antimicrobial peptides.

Authors:  Zhenping Wang; Yuping Lai; Jamie J Bernard; Daniel T Macleod; Anna L Cogen; Bernard Moss; Anna Di Nardo
Journal:  J Immunol       Date:  2011-12-02       Impact factor: 5.422

2.  The TNFR family members OX40 and CD27 link viral virulence to protective T cell vaccines in mice.

Authors:  Shahram Salek-Ardakani; Rachel Flynn; Ramon Arens; Hideo Yagita; Geoffrey L Smith; Jannie Borst; Stephen P Schoenberger; Michael Croft
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

3.  Expression of the A56 and K2 proteins is sufficient to inhibit vaccinia virus entry and cell fusion.

Authors:  Timothy R Wagenaar; Bernard Moss
Journal:  J Virol       Date:  2008-11-26       Impact factor: 5.103

Review 4.  Vaccinia virus vaccines: past, present and future.

Authors:  Bertram L Jacobs; Jeffrey O Langland; Karen V Kibler; Karen L Denzler; Stacy D White; Susan A Holechek; Shukmei Wong; Trung Huynh; Carole R Baskin
Journal:  Antiviral Res       Date:  2009-06-26       Impact factor: 5.970

Review 5.  The vaccinia virus A56 protein: a multifunctional transmembrane glycoprotein that anchors two secreted viral proteins.

Authors:  Brian C DeHaven; Kushol Gupta; Stuart N Isaacs
Journal:  J Gen Virol       Date:  2011-06-29       Impact factor: 3.891

6.  Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8.

Authors:  Minoru Kidokoro; Masato Tashiro; Hisatoshi Shida
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-07       Impact factor: 11.205

7.  Vaccinia virus A35R inhibits MHC class II antigen presentation.

Authors:  Kristina E Rehm; Ramsey F Connor; Gwendolyn J B Jones; Kenneth Yimbu; Rachel L Roper
Journal:  Virology       Date:  2009-12-02       Impact factor: 3.616

8.  Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens.

Authors:  José Luis Nájera; Carmen Elena Gómez; Juan García-Arriaza; Carlos Oscar Sorzano; Mariano Esteban
Journal:  PLoS One       Date:  2010-06-30       Impact factor: 3.240

9.  Effects of vaccinia virus uracil DNA glycosylase catalytic site and deoxyuridine triphosphatase deletion mutations individually and together on replication in active and quiescent cells and pathogenesis in mice.

Authors:  Frank S De Silva; Bernard Moss
Journal:  Virol J       Date:  2008-12-02       Impact factor: 4.099

10.  Vaccinia virus-encoded ribonucleotide reductase subunits are differentially required for replication and pathogenesis.

Authors:  Don B Gammon; Branawan Gowrishankar; Sophie Duraffour; Graciela Andrei; Chris Upton; David H Evans
Journal:  PLoS Pathog       Date:  2010-07-08       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.